Efficient production of bispecific antibody by FAST-Ig^TM and its application to NXT007 for the treatment of hemophilia A

References

• Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–18. doi:10.1038/s41573-019-0028-1. PMID: 31175342.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Bargou RC. T cell-engaging therapies — BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418–34. doi:10.1038/s41571-020-0347-5. PMID: 32242094.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–74. doi:10.1038/nm.2942. PMID: 23023498.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–18. doi:10.1056/NEJMoa1703068. PMID: 28691557.
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLos One. 2013;8:e57479. doi:10.1371/journal.pone.0057479. PMID: 23468998.
   PubMed Web of Science ®Google Scholar
• Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren P, Strohl WR, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021;296:100641. doi:10.1016/j.jbc.2021.100641. PMID: 33839159.
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet. 2022;399(10326):729–40. doi:10.1016/s0140-6736(22)00010-1. PMID: 35085502.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. The Lancet. 2022;399(10326):741–55. doi:10.1016/s0140-6736(22)00018-6. PMID: 35085503.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, Jiang Y, Fang H, Xing S, Fang Y, et al. The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med. 2021;13(9):e14291. doi:10.15252/emmm.202114291. PMID: 34431224.
   PubMed Web of Science ®Google Scholar
• Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. PMID: 34025638. doi:10.3389/fimmu.2021.626616.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307. PMID: 28071970.
   PubMed Web of Science ®Google Scholar
• Husain B, Ellerman D. Expanding the boundaries of biotherapeutics with bispecific antibodies. BioDrugs. 2018;32(5):441–64. doi:10.1007/s40259-018-0299-9. PMID: 30132211.
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. MAbs. 2009;1(2):128–41. doi:10.4161/mabs.1.2.7631. PMID: 20061822.
   PubMed Web of Science ®Google Scholar
• Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Engineering, Design And Selection. 2010;23(7):549–57. doi:10.1093/protein/gzq028. PMID: 20457695.
   PubMed Web of Science ®Google Scholar
• Bivi N, Moore T, Rodgers G, Denning H, Shockley T, Swearingen CA, Gelfanova V, Calderon B, Peterson DA, Hodsdon ME, et al. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. MAbs. 2019;11(5):861–69. doi:10.1080/19420862.2019.1612699. PMID: 31099718.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Croy JE, Schirtzinger L, Torgerson S, Breyer M, Wroblewski VJ. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. MAbs. 2016;8(5):969–82. doi:10.1080/19420862.2016.1178435. PMID: 27111637.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA. 2013;110(13):5145–50. doi:10.1073/pnas.1220145110. PMID: 23479652.
   PubMed Web of Science ®Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol. 2013;31(8):753–58. doi:10.1038/nbt.2621. PMID: 23831709.
   PubMed Web of Science ®Google Scholar
• Hofmann T, Schmidt J, Ciesielski E, Becker S, Rysiok T, Schütte M, Toleikis L, Kolmar H, Doerner A. Intein mediated high throughput screening for bispecific antibodies. MAbs. 2020;12(1):1731938. doi:10.1080/19420862.2020.1731938. PMID: 32151188.
   PubMed Web of Science ®Google Scholar
• Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D, Junttila TT, Han G, Sandoval W, Ovacik MA, et al. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs. 2017;9(2):213–30. doi:10.1080/19420862.2016.1267089. PMID: 27929752.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014;32(2):191–98. doi:10.1038/nbt.2797. PMID: 24463572.
   PubMed Web of Science ®Google Scholar
• Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem. 2015;290(12):7535–62. doi:10.1074/jbc.M114.620260. PMID: 25583986.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677–81. doi:10.1038/nbt0798-677. PMID: 9661204.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–21. doi:10.1093/protein/9.7.617. PMID: 8844834.
   PubMedGoogle Scholar
• Skegro D, Stutz C, Ollier R, Svensson E, Wassmann P, Bourquin F, Monney T, Gn S, Blein S. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem. 2017;292:9745–59. doi:10.1074/jbc.M117.782433. PMID: 28450393.
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. Seedbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Protein Engineering, Design And Selection. 2010;23(4):195–202. doi:10.1093/protein/gzp094. PMID: 20299542.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, inventors;. Chugai Pharmaceutical Co. Ltd, assignee. Methods for producing polypeptides by regulating polypeptide association. WO2006106905. 2006.
   Google Scholar
• Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, et al. An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017;9(410). doi: 10.1126/scitranslmed.aal4291. PMID: 28978751.
   PubMed Web of Science ®Google Scholar
• Shiraiwa H, Narita A, Kamata-Sakurai M, Ishiguro T, Sano Y, Hironiwa N, Tsushima T, Segawa H, Tsunenari T, Ikeda Y, et al. Engineering a bispecific antibody with a common light chain: identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974. Methods. 2019;154:10–20. doi:10.1016/j.ymeth.2018.10.005. PMID: 30326272.
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. Journal Of Biological Chemistry. 2010;285(25):19637–46. doi:10.1074/jbc.M110.117382. PMID: 20400508.
   PubMed Web of Science ®Google Scholar
• De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, de Kruif J. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G(1). Journal Of Biological Chemistry. 2017;292(35):14706–17. doi:10.1074/jbc.M117.793497. PMID: 28655766.
   PubMed Web of Science ®Google Scholar
• Gera N. The evolution of bispecific antibodies. Expert Opin Biol Ther. 2022;22:945–49. doi:10.1080/14712598.2022.2040987. PMID: 35147061.
   PubMed Web of Science ®Google Scholar
• Krah S, Schröter C, Eller C, Rhiel L, Rasche N, Beck J, Sellmann C, Günther R, Toleikis L, Hock B, et al. Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display. Protein Eng Des Sel. 2017;30:291–301. doi:10.1093/protein/gzw077. PMID: 28062646.
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. 2011;108(27):11187–92. doi:10.1073/pnas.1019002108. PMID: 21690412.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs. 2015;7(2):377–89. doi:10.1080/19420862.2015.1007816. PMID: 25621507.
   PubMed Web of Science ®Google Scholar
• Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. THE COVALENT STRUCTURE of an ENTIRE γG IMMUNOGLOBULIN MOLECULE. Proc Natl Acad Sci USA. 1969;63(1):78–85. doi:10.1073/pnas.63.1.78. PMID: 5257969.
   PubMed Web of Science ®Google Scholar
• Kabat EA WT PH, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest. Bethesda, MD: NIH; 1991.
   Google Scholar
• Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, Asanuma K, Funaki M, Ichiki M, Ikuta Y, et al. 2023. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state. bioRxiv. 2022.12.19.520692. doi:10.1101/2022.12.19.520692.
   Google Scholar
• Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293(4):865–81. doi:10.1006/jmbi.1999.3192. PMID: 10543973.
   PubMed Web of Science ®Google Scholar
• Zhou HX, Pang X. Electrostatic interactions in protein structure, folding, binding, and condensation. Chem Rev. 2018;118(4):1691–741. doi:10.1021/acs.chemrev.7b00305. PMID: 29319301.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, Sekimori Y, Orita T, Aso Y, Hattori K, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Engineering Design And Selection. 2010;23(8):667–77. doi:10.1093/protein/gzq034. PMID: 20576629.
   PubMed Web of Science ®Google Scholar
• Saul RJP FA. Fab fragment from human immunoglobulin Igg1 ( Hil, PDB entry 8FAB).
   Google Scholar
• De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol. 2008;8:620–26. doi:10.1016/j.coph.2008.08.002. PMID: 18775515.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Terry F, Cousens L, Martin W. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Rev Clin Pharmacol. 2013;6:651–62. doi:10.1586/17512433.2013.835698. PMID: 24164613.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”. Blood. 2008;112(8):3303–11. doi:10.1182/blood-2008-02-138073. PMID: 18660382.
   PubMed Web of Science ®Google Scholar
• Latypov RF, Hogan S, Lau H, Gadgil H, Liu D. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem. 2012;287:1381–96. doi:10.1074/jbc.M111.297697. PMID: 22084250.
   PubMed Web of Science ®Google Scholar
• Mazzer AR, Perraud X, Halley J, O’Hara J, Bracewell DG. Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A. 2015;1415:83–90. doi:10.1016/j.chroma.2015.08.068. PMID: 26346187.
   PubMed Web of Science ®Google Scholar
• Jin W, Xing Z, Song Y, Huang C, Xu X, Ghose S, Li ZJ. Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification. MAbs. 2019;11(8):1479–91. doi:10.1080/19420862.2019.1658493. PMID: 31441367.
   PubMed Web of Science ®Google Scholar
• Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res. 2008;25(7):1487–99. doi:10.1007/s11095-007-9516-9. PMID: 18172579.
   PubMed Web of Science ®Google Scholar
• Arosio P, Rima S, Morbidelli M. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates. Pharm Res. 2013;30(3):641–54. doi:10.1007/s11095-012-0885-3. PMID: 23054090.
   PubMed Web of Science ®Google Scholar
• Printz M, Friess W. Simultaneous detection and analysis of protein aggregation and protein unfolding by size exclusion chromatography with post column addition of the fluorescent dye BisANS. J Pharm Sci. 2012;101:826–37. doi:10.1002/jps.22808. PMID: 22095720.
   PubMed Web of Science ®Google Scholar
• Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451–61. doi:10.1007/s00253-016-7388-9. PMID: 26936774.
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, Funaki M, Yoshihashi K, Kitazawa T, Muto A, Kojima T, Nakamura S, Hattori K. Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. MAbs. 2015;7(1):120–28. doi:10.4161/19420862.2015.989028. PMID: 25524207.
   PubMed Web of Science ®Google Scholar
• Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Mølhøj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al. Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions. PLos One. 2014;9(6):e100736. doi:10.1371/journal.pone.0100736. PMID: 24959685.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs. 2011;3(3):243–52. doi:10.4161/mabs.3.3.15234. PMID: 21406966.
   PubMed Web of Science ®Google Scholar
• Warwicker J, Charonis S, Curtis RA. Lysine and arginine content of proteins: computational analysis suggests a new tool for solubility design. Mol Pharm. 2014;11:294–303. doi:10.1021/mp4004749. PMID: 24283752.
   PubMedGoogle Scholar
• Austerberry JI, Dajani R, Panova S, Roberts D, Golovanov AP, Pluen A, van der Walle CF, Uddin S, Warwicker J, Derrick JP, et al. The effect of charge mutations on the stability and aggregation of a human single chain Fv fragment. Eur J Pharm Biopharm. 2017;115:18–30. doi:10.1016/j.ejpb.2017.01.019. PMID: 28161552.
   PubMed Web of Science ®Google Scholar
• Austerberry JI, Thistlethwaite A, Fisher K, Golovanov AP, Pluen A, Esfandiary R, van der Walle CF, Warwicker J, Derrick JP, Curtis R. Arginine to lysine mutations increase the aggregation stability of a single-chain variable fragment through unfolded-state interactions. Biochemistry. 2019;58(32):3413–21. doi:10.1021/acs.biochem.9b00367. PMID: 31314511.
   PubMed Web of Science ®Google Scholar
• Rahman N, Islam MM, Kibria MG, Unzai S, Kuroda Y. A systematic mutational analysis identifies a 5-residue proline tag that enhances the in vivo immunogenicity of a non-immunogenic model protein. FEBS Open Bio. 2020;10(10):1947–56. doi:10.1002/2211-5463.12941. PMID: 33017095.
   PubMed Web of Science ®Google Scholar
• Feige MJ, Hendershot LM, Buchner J. How antibodies fold. Trends Biochem Sci. 2010;35:189–98. doi:10.1016/j.tibs.2009.11.005. PMID: 20022755.
   PubMed Web of Science ®Google Scholar
• Feige MJ, Groscurth S, Marcinowski M, Shimizu Y, Kessler H, Hendershot LM, Buchner J. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell. 2009;34:569–79. doi:10.1016/j.molcel.2009.04.028. PMID: 19524537.
   PubMed Web of Science ®Google Scholar
• Knarr G, Gething MJ, Modrow S, Buchner J. BiP binding sequences in antibodies. J Biol Chem. 1995;270:27589–94. doi:10.1074/jbc.270.46.27589. PMID: 7499221.
   PubMed Web of Science ®Google Scholar
• Marcinowski M, Rosam M, Seitz C, Elferich J, Behnke J, Bello C, Feige MJ, Becker CF, Antes I, Buchner J. Conformational selection in substrate recognition by Hsp70 chaperones. J Mol Biol. 2013;425:466–74. doi:10.1016/j.jmb.2012.11.030. PMID: 23207294.
   PubMed Web of Science ®Google Scholar
• Joshi KK, Phung W, Han G, Yin Y, Kim I, Sandoval W, Carter PJ. Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells. MAbs. 2019;11(7):1254–65. doi:10.1080/19420862.2019.1640549. PMID: 31286843.
   PubMed Web of Science ®Google Scholar
• Gong D, Riley TP, Bzymek KP, Correia AR, Li D, Spahr C, Robinson JH, Case RB, Wang Z, Garces F. Rational selection of building blocks for the assembly of bispecific antibodies. MAbs. 2021;13(1):1870058. doi:10.1080/19420862.2020.1870058. PMID: 33397191.
   PubMed Web of Science ®Google Scholar
• Regula JT, Imhof-Jung S, Mølhøj M, Benz J, Ehler A, Bujotzek A, Schaefer W, Klein C, Bradbury A. Variable heavy–variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. Protein Engineering, Design And Selection. 2018;31(7–8):289–99. doi:10.1093/protein/gzy021. PMID: 30169707.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Emrich T, Chebon S, Fernandez E, Petry C, Yoneyama K, Kiialainen A, Howard M, Niggli M, Paz-Priel I, et al. Low immunogenicity of emicizumab in persons with haemophilia a. Haemophilia. 2021;27(6):984–92. doi:10.1111/hae.14398. PMID: 34480814.
   PubMed Web of Science ®Google Scholar